CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Generic Name||Nanoliposomal Irinotecan|
|Indication||Metastatic Pancreatic Cancer|
|Funding Request||For second-line treatment of metastatic adenocarcinoma of the pancreas in combination with 5-fluorouracil (5-FU) and leucovorin in adult patients who have been previously treated with gemcitabine-based therapy|
|Pre Noc Submission||Yes|
|Manufacturer||Baxalta Canada Corporation|
|Sponsor||Baxalta Canada Corporation|
|Clarification||The submitter notified pCODR that they will not be filing the submission.|
|Submission Date (Target Date)|
|Stakeholder Input Deadline (target date based on target submission date) ‡|
|Check-point meeting (target date)|
|pERC Meeting (target date)|
|Initial Recommendation Issued (target date)|
|Feedback Deadline (target date) ‡|
|pERC Reconsideration Meeting (target date)|
|Final Recommendation Issued (target date)|
|Notification to Implement Issued|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.